Cat. No. | Product name | CAS No. |
DC11704 |
CFI-401870
A potent, selective, orally active Mps1 (TTK) inhibitor with IC50 of 3.1 nM. |
1599460-95-3 |
DC11677 |
CCT-271850
A potent, selective, orally bioavailable Mps1 kinase inhibitor with IC50 of 11 nM. |
1578244-34-4 |
DC7072 |
AZ3146
Featured
AZ3146 is a potent and selective monopolar spindle 1 (Mps1) kinase inhibitor (IC50 = 35 nM); less potent to FAK, JNK1, JNK2, and Kit. |
1124329-14-1 |
DC9679 |
BAY1217389
Featured
BAY1217389 is an orally bioavailable, selective inhibitor of the serine/threonine kinase monopolar spindle 1 (Mps1, TTK), with potential antineoplastic activity. |
1554458-53-5 |
DC7470 |
MPI-0479605
Featured
MPI-0479605 is an ATP competitive and selective inhibitor of mitotic kinase Mps1 with IC50 of 1.8 nM, >40-fold selectivity over other kinases. |
1246529-32-7 |
DC8119 |
Mps1-IN-2
Featured
Mps1-IN-2 is a potent Mps1 kianse inhibitor with IC50 value of 145 nM. |
1228817-38-6 |
DC5087 |
Mps1-IN-1
Mps1-IN-1 is a highly potent and selectibe Mpsl inhibitor with IC50 of 367 nM; >1000-fold selectivity relative to the 352 member kinase panel with the major exceptions of Alk and Ltk. |
1125593-20-5 |
DC7866 |
NMS-P715
Featured
NMS-P715 is the first selective, ATP-competitive and orally bioavailable MPS1 small-molecule inhibitor(IC50=8 nM); selectively reduces cancer cell proliferation, leaving normal cells almost unaffected. |
1202055-32-0 |
DC28264 |
TC-Mps1-12
TC-Mps1-12 is a potent and selective monopolar spindle 1 (Mps1) inhibitor, with an IC50 of 6.4 nM. |
1206170-62-8 |
DC50255 |
RMS-07
RMS-07 is a covalent Monopolar Spindle Kinase 1 (MPS1/TTK) inhibitor, with an apparent IC50 of 13.1 nM. RMS-07 targets a poorly conserved cysteine in the kinase's hinge region. |
2645409-78-3 |
DC70063 |
CFI-402257
A potent and selective Mps1/TTK kinase inhibitor with Ki of 0.1 nM and cellular Mps1 EC50 of 6.5 nM. |
1610759-22-2 |
DC70740 |
RMS-07
RMS-07 (RMS 07) is the first potent, selective irreversible covalent inhibitor of Monopolar spindle kinase 1 (MPS1/TTK) with IC50 of 13 nM, Ki of 0.83 nM; demonstrated intracellular target engagement with IC50 of 22.4 nM, shows a high selectivity against MAPKAPK2/3, FGFR4, p70S6Kβ (IC50>1 uM); RMS-07 induced cell cycle arrest with a prolonged G2/M phase, downregulated cyclin B1, whereas it upregulated p53, p21, and phospho-γH2A.X, enhanced cleaved PARP levels; RMS-07 attenuates cancer cell proliferation, RMS-07 and Navitoclax synergistically inhibit hepatocellular carcinoma cell proliferation. |
2645409-78-3 |